The contradictive actions between the serotonergic and noradrenergic transmissions on the thalamocortical glutamatergic transmission possibly, at least partially, can explain the clinical advantage of selective serotonin transporter inhibitors to major depression, compared with selective norepinephrine transporter inhibitors. The gene discussed is SLC6A2; the disease is major depressive disorder.